Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology

Kathryn A. Kvam; Michael Benatar; Alisa Brownlee; Tracie Caller; Rohit R. Das; Phil Green; Sherry Kolodziejczak; John Russo; Danica Sanders; Nadia Sethi; Kara Stavros; Julie Stierwalt; Nancy Giles Walters; Amy Bennett; Scott R. Wessels; Benjamin Rix Brooks

doi:10.1212/WNL.0000000000207166

Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology

Kathryn A. Kvam, Michael Benatar, Alisa Brownlee, Tracie Caller, Rohit R. Das, Phil Green, Sherry Kolodziejczak, John Russo, Danica Sanders, Nadia Sethi, Kara Stavros, Julie Stierwalt, Nancy Giles Walters, Amy Bennett, Scott R. Wessels, Benjamin Rix Brooks

Neurology

Research output: Contribution to journal › Article › peer-review

Abstract

The estimated prevalence of amyotrophic lateral sclerosis (ALS) is approximately 5.2-7.9 people per 100,000 in the United States,1,2 with a worldwide ALS estimate of 4.42 per 1,000,000 population.3 Patients with ALS have progressive arm and leg weakness, speech, swallowing, and respiratory impairments, and frequent cognitive/behavioral dysfunction. Median tracheostomy-free survival from onset of weakness is 34.7 months, but progression rates vary substantially between individuals.4 Although pharmacologic treatment options remain limited, judicious use of noninvasive ventilation, adequate nutritional support, and multidisciplinary care serve as the background for a landscape that continues to evolve with increasing availability of neuroprotective treatments and targeted genetic therapies on both a clinical5 and research basis.6,7.

Original language	English (US)
Pages (from-to)	223-232
Number of pages	10
Journal	Neurology
Volume	101
Issue number	5
DOIs	https://doi.org/10.1212/WNL.0000000000207166
State	Published - Aug 1 2023

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000207166

Cite this

Kvam, K. A., Benatar, M., Brownlee, A., Caller, T., Das, R. R., Green, P., Kolodziejczak, S., Russo, J., Sanders, D., Sethi, N., Stavros, K., Stierwalt, J., Giles Walters, N., Bennett, A., Wessels, S. R., & Brooks, B. R. (2023). Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology. Neurology, 101(5), 223-232. https://doi.org/10.1212/WNL.0000000000207166

Kvam, KA, Benatar, M, Brownlee, A, Caller, T, Das, RR, Green, P, Kolodziejczak, S, Russo, J, Sanders, D, Sethi, N, Stavros, K, Stierwalt, J, Giles Walters, N, Bennett, A, Wessels, SR & Brooks, BR 2023, 'Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology', Neurology, vol. 101, no. 5, pp. 223-232. https://doi.org/10.1212/WNL.0000000000207166

@article{9b340cdae3c14eef85b21d54c7954f21,

title = "Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology",

abstract = "The estimated prevalence of amyotrophic lateral sclerosis (ALS) is approximately 5.2-7.9 people per 100,000 in the United States,1,2 with a worldwide ALS estimate of 4.42 per 1,000,000 population.3 Patients with ALS have progressive arm and leg weakness, speech, swallowing, and respiratory impairments, and frequent cognitive/behavioral dysfunction. Median tracheostomy-free survival from onset of weakness is 34.7 months, but progression rates vary substantially between individuals.4 Although pharmacologic treatment options remain limited, judicious use of noninvasive ventilation, adequate nutritional support, and multidisciplinary care serve as the background for a landscape that continues to evolve with increasing availability of neuroprotective treatments and targeted genetic therapies on both a clinical5 and research basis.6,7.",

author = "Kvam, {Kathryn A.} and Michael Benatar and Alisa Brownlee and Tracie Caller and Das, {Rohit R.} and Phil Green and Sherry Kolodziejczak and John Russo and Danica Sanders and Nadia Sethi and Kara Stavros and Julie Stierwalt and {Giles Walters}, Nancy and Amy Bennett and Wessels, {Scott R.} and Brooks, {Benjamin Rix}",

note = "Publisher Copyright: {\textcopyright} American Academy of Neurology.",

year = "2023",

month = aug,

day = "1",

doi = "10.1212/WNL.0000000000207166",

language = "English (US)",

volume = "101",

pages = "223--232",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "5",

}

TY - JOUR

T1 - Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update

T2 - Quality Improvement in Neurology

AU - Kvam, Kathryn A.

AU - Benatar, Michael

AU - Brownlee, Alisa

AU - Caller, Tracie

AU - Das, Rohit R.

AU - Green, Phil

AU - Kolodziejczak, Sherry

AU - Russo, John

AU - Sanders, Danica

AU - Sethi, Nadia

AU - Stavros, Kara

AU - Stierwalt, Julie

AU - Giles Walters, Nancy

AU - Bennett, Amy

AU - Wessels, Scott R.

AU - Brooks, Benjamin Rix

PY - 2023/8/1

Y1 - 2023/8/1

N2 - The estimated prevalence of amyotrophic lateral sclerosis (ALS) is approximately 5.2-7.9 people per 100,000 in the United States,1,2 with a worldwide ALS estimate of 4.42 per 1,000,000 population.3 Patients with ALS have progressive arm and leg weakness, speech, swallowing, and respiratory impairments, and frequent cognitive/behavioral dysfunction. Median tracheostomy-free survival from onset of weakness is 34.7 months, but progression rates vary substantially between individuals.4 Although pharmacologic treatment options remain limited, judicious use of noninvasive ventilation, adequate nutritional support, and multidisciplinary care serve as the background for a landscape that continues to evolve with increasing availability of neuroprotective treatments and targeted genetic therapies on both a clinical5 and research basis.6,7.

AB - The estimated prevalence of amyotrophic lateral sclerosis (ALS) is approximately 5.2-7.9 people per 100,000 in the United States,1,2 with a worldwide ALS estimate of 4.42 per 1,000,000 population.3 Patients with ALS have progressive arm and leg weakness, speech, swallowing, and respiratory impairments, and frequent cognitive/behavioral dysfunction. Median tracheostomy-free survival from onset of weakness is 34.7 months, but progression rates vary substantially between individuals.4 Although pharmacologic treatment options remain limited, judicious use of noninvasive ventilation, adequate nutritional support, and multidisciplinary care serve as the background for a landscape that continues to evolve with increasing availability of neuroprotective treatments and targeted genetic therapies on both a clinical5 and research basis.6,7.

UR - http://www.scopus.com/inward/record.url?scp=85166700064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85166700064&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000207166

DO - 10.1212/WNL.0000000000207166

M3 - Article

C2 - 37524529

AN - SCOPUS:85166700064

SN - 0028-3878

VL - 101

SP - 223

EP - 232

JO - Neurology

JF - Neurology

IS - 5

ER -

Amyotrophic Lateral Sclerosis Quality Measurement Set 2022 Update: Quality Improvement in Neurology

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this